U.S. market Closed. Opens in 16 hours 52 minutes

RPRX | Royalty Pharma plc Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for RPRX we got that it has average fundamentals where Valuation is considered to be slightly undervalued, Profitability is moderate, Growth is on medium level and Health is strong.

Valuation (67%)

Company Industry
P/E Ratio (TTM) 18.46 -15.40
PEG Ratio (TTM) 2.65 -1.28
P/S Ratio (TTM) 5.52 47.91
P/B Ratio (TTM) 1.92 21.47
P/FCF Ratio (TTM) 31.14 5.35
Price to 5YR AVG Earnings Ratio 11.95 -0.30
Price to 5YR AVG FCF Ratio 5.46 -7.28

Profitability (55%)

Company Industry
ROA (TTM) 3.81% -2.96%
ROE (TTM) 10.50% 23.42%
Net Profit Margin (TTM) 30.09% -894.56%
ROIC 5YR AVG 13.24% 16.62%

Growth (60%)

4QTR AVG 3YR AVG 5YR AVG
EPS 623.97% -9.09% 475.67%
Revenue 0.17% 8.64% 5.78%
Net Income 613.25% -3.92% 489.34%
Cash Flow 3.73% 8.07% 14.38%

Health (61%)

Company Industry
Current Ratio (TTM) 9.35 5.73
Quick Ratio (TTM) 9.35 5.45
D/E Ratio (TTM) 1.17 -14.53
Interest Coverage (TTM) 5.16 3.88
Piotroski F-Score 6 5
Altman Z-Score 1.64 13.58
LTL to 5YR AVG FCF 2.72 0.21
Shares Outstanding Growth 5YR AVG 4.84% 117.96%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙